Cambridge-based data company Qureight has raised £1.5 million seed funding to deliver the next generation of its ground-breaking platform and capitalise on its vision to house the world’s largest collection of data from complex diseases. The round was led by Playfair Capital, with participation from life sciences funds Meltwind, Ascension, and Cambridge Angels.
The startup uses cloud-based technology to assist in the structuring of image and paired clinical metadata in complex diseases. By structuring data in this way, it allows for the development of AI-based tools to better understand diseases including lung fibrosis, complex cancers and covid-19. Clients currently using the Qureight platform include Takeda, Galapagos, and Roche.
Dr. Muhunthan Thillai, CEO, Qureight said: “Existing treatments for lung fibrosis are costly and clinical trials to find new drugs are often very large – needing many patients to look for an outcome. Our technology will allow biopharma companies to recruit fewer patients for clinical trials and more precisely target the right kind of patients – saving money and producing better outcomes with a personalised approach to drug development."
Dr. Alessandro Ruggiero, Chief Scientific Officer, Qureight said: “Our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas."